{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:26:40Z","timestamp":1765888000010,"version":"3.37.3"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["167044"],"award-info":[{"award-number":["167044"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To explore the antihyperglycaemic and antidiabetic effects and to determine the acute toxicity of 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (ENP-9).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The antihyperglycaemic effect of ENP-9 (50 mg\/kg) was determined by oral glucose tolerance test (OGTT). Also, the acute (16, 50 and 160 mg\/kg) and subacute (50 mg\/kg\/day for 10 days) antidiabetic effects of ENP-9 were determined. After subacute treatment, blood samples were analysed to determine glucose and lipid profiles. Also, an acute toxicity determination of ENP-9 was conducted followed the OECD recommendation. Molecular docking was performed using AutoDock 4.2.6 at human cannabinoid receptor 1 (PDB code 5TGZ).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Acute Administration of ENP-9 showed significant antidiabetic effect and decreased the maximum OGTT peak, compared to the control group (P &amp;lt; 0.05). Moreover, the 10 days treatment induced a decrease in plasma glucose levels, being significant at the end of the experiments (P &amp;lt; 0.05); however, triacylglycerols and cholesterol were not modified. Finally, LD50 of ENP-9 was estimated to be greater than 2000 mg\/kg. Molecular docking suggests that ENP-9 may act as rimonabant does.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ENP-9 showed significant antihyperglycaemic and antidiabetic properties and also was demonstrated to be safety in the studied doses, which might allow future studies for its potential development as antidiabetic agent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12933","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T05:55:06Z","timestamp":1526622906000},"page":"1031-1039","source":"Crossref","is-referenced-by-count":3,"title":["Acute and subacute antidiabetic studies of ENP-9, a new 1,5-diarylpyrazole derivative"],"prefix":"10.1093","volume":"70","author":[{"given":"Eduardo","family":"Hern\u00e1ndez-V\u00e1zquez","sequence":"first","affiliation":[{"name":"Facultad de Qu\u00edmica, Departamento de Farmacia, Universidad Nacional Aut\u00f3noma de M\u00e9xico , M\u00e9xico,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Young-Peralta","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos , Cuernavaca, Morelos,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litzia","family":"Cer\u00f3n-Romero","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos , Cuernavaca, Morelos,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Garc\u00eda-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos , Cuernavaca, Morelos,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-0744","authenticated-orcid":false,"given":"Samuel","family":"Estrada-Soto","sequence":"additional","affiliation":[{"name":"Facultad de Farmacia, Universidad Aut\u00f3noma del Estado de Morelos , Cuernavaca, Morelos,","place":["M\u00e9xico"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"2024103012314206500_jphp12933-cit-0001","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2016.04.077","article-title":"The therapeutic voyage of pyrazole and its analogs: a review","volume":"120","author":"Khan","year":"2016","journal-title":"Eur J Med Chem"},{"key":"2024103012314206500_jphp12933-cit-0002","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1016\/j.bmcl.2011.07.057","article-title":"New pyrazolyl and thienyl aminohydantoins as potent BACE1 inhibitors: exploring the S2\u2019 region","volume":"21","author":"Malamas","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0003","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1016\/j.bmcl.2010.09.095","article-title":"Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain","volume":"20","author":"Lo","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0004","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ejmech.2013.03.042","article-title":"Synthesis, anticancer activity and photophysical properties of novel substituted 2-oxo-2H-chromenylpyrazolecarboxylates","volume":"65","author":"Kumar","year":"2013","journal-title":"Eur J Med Chem"},{"key":"2024103012314206500_jphp12933-cit-0005","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.bmcl.2011.02.033","article-title":"Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor","volume":"21","author":"Hoveyda","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0006","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1016\/j.bmcl.2012.05.063","article-title":"Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlrophenyl)-4-substituted pyrazole derivatives","volume":"22","author":"Pathak","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejmech.2015.02.038","article-title":"New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents","volume":"94","author":"Bekhit","year":"2015","journal-title":"Eur J Med Chem"},{"key":"2024103012314206500_jphp12933-cit-0008","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1016\/j.bmcl.2012.08.119","article-title":"Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: docking, synthesis and pharmacological evaluation as a potential anti-inflammatory agents","volume":"22","author":"Yewale","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0009","doi-asserted-by":"crossref","first-page":"10098","DOI":"10.1016\/j.bmc.2008.10.023","article-title":"Antiobesity designed multiple ligands: synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents","volume":"16","author":"Alvarado","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"2024103012314206500_jphp12933-cit-0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejmech.2015.06.010","article-title":"1,5-Diarylpyrazole and vanillin hybrids: synthesis, biological activity and DFT studies","volume":"100","author":"Hern\u00e1ndez-V\u00e1zquez","year":"2015","journal-title":"Eur J Med Chem"},{"key":"2024103012314206500_jphp12933-cit-0011","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.bmc.2016.04.007","article-title":"Synthesis and molecular docking of N\u2019-arylidene-5-(4-chlorophenyl)-1-(3,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbohydrazides as novel hypoglycemic and antioxidant dual agents","volume":"24","author":"Hern\u00e1ndez-V\u00e1zquez","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"2024103012314206500_jphp12933-cit-0012","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.bmcl.2014.11.029","article-title":"Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRbeta","volume":"25","author":"Kick","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0013","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nn1457","article-title":"Endocannabinoid control of food intake and energy balance","volume":"8","author":"Di Marzo","year":"2005","journal-title":"Nat Neurosci"},{"key":"2024103012314206500_jphp12933-cit-0014","first-page":"535","article-title":"Cannabinoid-1 receptor antagonists in type-2 diabetes. Cannabinoid-1 receptor antagonists in type-2 diabetes","volume":"21","author":"Scheen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2024103012314206500_jphp12933-cit-0015","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1172\/JCI42551","article-title":"Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity","volume":"120","author":"Tam","year":"2010","journal-title":"Clin Invest"},{"key":"2024103012314206500_jphp12933-cit-0016","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1365-2826.2008.01728.x","article-title":"The endocannabinoid system and energy metabolism","volume":"20","author":"Bellocchio","year":"2008","journal-title":"J Neuroendocrinol"},{"key":"2024103012314206500_jphp12933-cit-0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000114255","article-title":"Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade","volume":"1","author":"Engeli","year":"2008","journal-title":"Obes Facts"},{"key":"2024103012314206500_jphp12933-cit-0018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejmech.2013.07.054","article-title":"Synthesis, hypoglycemic activity and molecular modeling studies of pyrazole-3-carbohydrazides designed by a CoMFA model","volume":"69","author":"Hern\u00e1ndez-V\u00e1zquez","year":"2013","journal-title":"Eur J Med Chem"},{"key":"2024103012314206500_jphp12933-cit-0019","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-2002-32894","article-title":"Recommended testing in diabetes research","volume":"68","author":"Verspohl","year":"2002","journal-title":"Planta Med"},{"key":"2024103012314206500_jphp12933-cit-0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cbi.2015.11.032","article-title":"Challenges and issues with streptozotocin-induced diabetes \u2013 a clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics","volume":"244","author":"Goyal","year":"2016","journal-title":"Chem Biol Interact"},{"key":"2024103012314206500_jphp12933-cit-0021","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1248\/bpb.29.1110","article-title":"Strain differences in the diabetogenic activity of streptozotocin in mice","volume":"6","author":"Hayashi","year":"2006","journal-title":"Biol Pharm Bull"},{"key":"2024103012314206500_jphp12933-cit-0022","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.vascn.2015.11.004","article-title":"Experimental diabetes induced by alloxan and streptozotocin: the current state of the art","volume":"78","author":"Radenkov\u00edc","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2024103012314206500_jphp12933-cit-0023","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1463-1326.2008.00869.x","article-title":"Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation","volume":"10","author":"Ortiz-Andrade","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2024103012314206500_jphp12933-cit-0024","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.bmcl.2016.02.082","article-title":"In vitro and in silico PTP-1B inhibition and in vivo antidiabetic activity of semisynthetic moronic acid derivatives","volume":"26","author":"Cer\u00f3n-Romero","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jep.2006.07.002","article-title":"\u03b1-Glucosidase inhibitory activity of the methanolic extract from tournefortia hartwegiana: an anti-hyperglycemic agent","volume":"109","author":"Ortiz-Andrade","year":"2007","journal-title":"J Ethnopharmacol"},{"volume-title":"Draft Proposal for a Revised Guideline 413, Guidelines for the Testing Of Chemicals","year":"2008","author":"OECD","key":"2024103012314206500_jphp12933-cit-0026"},{"key":"2024103012314206500_jphp12933-cit-0027","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"16","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"volume-title":"The PyMOL Molecular Graphics System","key":"2024103012314206500_jphp12933-cit-0028"},{"key":"2024103012314206500_jphp12933-cit-0029","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/ml100164p","article-title":"Drawing the PDB: protein\u2212ligand complexes in two dimensions","volume":"1","author":"Stierand","year":"2010","journal-title":"Med Chem Lett"},{"key":"2024103012314206500_jphp12933-cit-0030","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200700010","article-title":"From modeling to medicinal chemistry: automatic generation of two-dimensional complex diagrams","volume":"2","author":"Stierand","year":"2007","journal-title":"ChemMedChem"},{"key":"2024103012314206500_jphp12933-cit-0031","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.bjp.0702127","article-title":"The action of the cannabinoid receptor antagonist SR141716A in the rat isolated mesenteric artery","volume":"125","author":"White","year":"1998","journal-title":"Br J Pharmacol"},{"key":"2024103012314206500_jphp12933-cit-0032","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCO.0b013e3282fcea11","article-title":"Inhibitors of cannabinoid receptors and glucose metabolism","volume":"11","author":"Scheen","year":"2008","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2024103012314206500_jphp12933-cit-0033","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.diabet.2007.02.001","article-title":"Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients","volume":"33","author":"Lafontan","year":"2007","journal-title":"Diabetes Metab"},{"key":"2024103012314206500_jphp12933-cit-0034","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/JME-12-0037","article-title":"Inhibition of cannabinoid CB1 receptor upregulates Slc2a4 expression via nuclear factor-\u03baB and sterol regulatory element-binding protein-1 in adipocytes","volume":"49","author":"Furuya","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"2024103012314206500_jphp12933-cit-0035","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s00125-011-2302-6","article-title":"Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice","volume":"54","author":"Bajzer","year":"2011","journal-title":"Diabetologia"},{"key":"2024103012314206500_jphp12933-cit-0036","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3109\/15563650.2013.784774","article-title":"Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs","volume":"51","author":"Al-Abri","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"key":"2024103012314206500_jphp12933-cit-0037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","article-title":"Drug treatments for obesity: orlistat, sibutramine, and rimonabant","volume":"369","author":"Padwal","year":"2007","journal-title":"Lancet"},{"key":"2024103012314206500_jphp12933-cit-0038","doi-asserted-by":"crossref","first-page":"E624","DOI":"10.1152\/ajpendo.00072.2012","article-title":"Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates","volume":"303","author":"Vaidyanathan","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2024103012314206500_jphp12933-cit-0039","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2017.03.036","article-title":"Antidiabetic, antidyslipidemic and toxicity profile of ENV-2: a potent pyrazole derivative against diabetes and related diseases","volume":"803","author":"Hern\u00e1ndez-V\u00e1zquez","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"2024103012314206500_jphp12933-cit-0040","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.2337\/db08-0161","article-title":"Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats","volume":"57","author":"Nogueiras","year":"2008","journal-title":"Diabetes"},{"key":"2024103012314206500_jphp12933-cit-0041","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00044-010-9398-y","article-title":"PASS-assisted exploration of new therapeutic potential of natural products","volume":"20","author":"Goel","year":"2011","journal-title":"Med Chem Res"},{"key":"2024103012314206500_jphp12933-cit-0042","first-page":"187","article-title":"Design, synthesis, in silico toxicity prediction, molecular docking, and evaluation of novel pyrazole derivatives as potential antiproliferative agents","volume":"15","author":"Parameshwar","year":"2016","journal-title":"EXCLI J"},{"key":"2024103012314206500_jphp12933-cit-0043","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00044-014-1299-z","article-title":"Potential utility of adenosine 5\u2032-ester prodrugs to enhance its plasma half-life: synthesis and molecular docking studies","volume":"24","author":"Hern\u00e1ndez-V\u00e1zquez","year":"2015","journal-title":"Med Chem Res"},{"key":"2024103012314206500_jphp12933-cit-0044","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17460441.2016.1190706","article-title":"Using reverse docking for target identification and its applications for drug discovery","volume":"11","author":"Lee","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"2024103012314206500_jphp12933-cit-0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bcp.2017.10.014","article-title":"Kinetics of human cannabinoid 1 (CB1) receptor antagonists: structurekinetics relationships (SKR) and implications for insurmountable antagonism","volume":"151","author":"Lizi","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"2024103012314206500_jphp12933-cit-0046","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/cbdd.13069","article-title":"Novel pyrrolocycloalkylpyrazole analogues as CB1 ligands","volume":"91","author":"Asproni","year":"2018","journal-title":"Chem Biol Drug Des"},{"key":"2024103012314206500_jphp12933-cit-0047","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1124\/mol.107.034645","article-title":"Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7","volume":"71","author":"Kapur","year":"2007","journal-title":"Mol Pharmacol"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/8\/1031\/60223813\/jphp12933.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/8\/1031\/60223813\/jphp12933.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:41:58Z","timestamp":1730310118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/70\/8\/1031\/6121784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12933","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,8,1]]}}}